1.
Belgian expert opinion: how to reduce the residual risk in atherogenic dyslipidaemic patients: place of fibrates.
2.
3.
4.
5.
6.
7.
8.
9.
The impact of reimbursement criteria on the appropriateness of 'statin' prescribing.